메뉴 건너뛰기




Volumn 10, Issue 10, 2010, Pages 1529-1543

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia

Author keywords

cladribine; CLL; combined therapy; fludarabine; NHL; pentostatin; R FC; refractory; relapsed; rituximab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; APOLIZUMAB; BENDAMUSTINE; CD40 MONOCLONAL ANTIBODY; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; GRANULOCYTE COLONY STIMULATING FACTOR; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRU 016; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 77958061246     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.132     Document Type: Review
Times cited : (22)

References (101)
  • 1
    • 3042516892 scopus 로고    scopus 로고
    • The clinical and epidemiological burden of chronic lymphocytic leukaemia
    • Redaelli A, Laskin BL, Stephens JM et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care 13, 279-1267 (2004).
    • (2004) Eur. J. Cancer Care , vol.13 , pp. 279-1267
    • Redaelli, A.1    Laskin, B.L.2    Stephens, J.M.3
  • 3
    • 0019427092 scopus 로고
    • A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
    • Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206 (1981).
    • (1981) Cancer , vol.48 , pp. 198-206
    • Binet, J.L.1    Auquier, A.2    Dighiero, G.3
  • 5
    • 15244342190 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia: Novel prognostic factors and their relevance for risk-adapted therapeutic strategies
    • Montiilo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90, 391-399 (2005).
    • (2005) Haematologica , vol.90 , pp. 391-399
    • Montiilo, M.1    Hamblin, T.2    Hallek, M.3    Montserrat, E.4    Morra, E.5
  • 7
    • 0344729013 scopus 로고    scopus 로고
    • Chlorambucil in indolent chronic lymphocytic leukemia
    • Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. J. Med. 338, 1506-1514 (1998).
    • (1998) N. Engl. J. Med. , vol.338 , pp. 1506-1514
    • Dighiero, G.1    Maloum, K.2    Desablens, B.3
  • 8
    • 0033583824 scopus 로고    scopus 로고
    • Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials
    • CLL Trialists Collaborative Group
    • CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst. 91, 861-868 (1999).
    • (1999) J. Natl Cancer Inst. , vol.91 , pp. 861-868
  • 9
    • 70350720141 scopus 로고    scopus 로고
    • First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
    • German CLL Study Group (GCLLSG)
    • Eichhorst BF, Busch R, Stilgenbauer S et al. German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382-3391 (2009).
    • (2009) Blood , vol.114 , Issue.16 , pp. 3382-3391
    • Eichhorst, B.F.1    Busch, R.2    Stilgenbauer, S.3
  • 10
    • 0036273331 scopus 로고    scopus 로고
    • Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
    • Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16, 1015-1027 (2002).
    • (2002) Leukemia , vol.16 , pp. 1015-1027
    • Robak, T.1    Kasznicki, M.2
  • 11
    • 0842322870 scopus 로고    scopus 로고
    • High dose chlorambucil in the treatment of lymphoid malignancies
    • Nicolle A, Proctor SJ, Summerfield GP. High dose chlorambucil in the treatment of lymphoid malignancies. Leuk. Lymphoma 45, 271-275 (2004).
    • (2004) Leuk. Lymphoma , vol.45 , pp. 271-275
    • Nicolle, A.1    Proctor, S.J.2    Summerfield, G.P.3
  • 12
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
    • (2000) N. Engl. J. Med. , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 13
    • 0034667537 scopus 로고    scopus 로고
    • Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
    • Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96, 2723-2729 (2000).
    • (2000) Blood , vol.96 , pp. 2723-2729
    • Robak, T.1    Blonski, J.Z.2    Kasznicki, M.3
  • 14
    • 63449116519 scopus 로고    scopus 로고
    • Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases
    • Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14(3), 1183-1226 (2009).
    • (2009) Molecules , vol.14 , Issue.3 , pp. 1183-1226
    • Robak, T.1    Korycka, A.2    Lech-Maranda, E.3    Robak, P.4
  • 15
    • 26944435896 scopus 로고    scopus 로고
    • Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)
    • Robak T, Blonski JZ, Kasznicki M et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med. Sci. Monit. 11, 71-79 (2005).
    • (2005) Med. Sci. Monit. , vol.11 , pp. 71-79
    • Robak, T.1    Blonski, J.Z.2    Kasznicki, M.3
  • 16
    • 0035889147 scopus 로고    scopus 로고
    • Randomized comparison of fludarabine,CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
    • Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98, 2319-2325 (2001).
    • (2001) Blood , vol.98 , pp. 2319-2325
    • Leporrier, M.1    Chevret, S.2    Cazin, B.3
  • 17
    • 0032830965 scopus 로고    scopus 로고
    • In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
    • Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94, 2836-2843 (1999).
    • (1999) Blood , vol.94 , pp. 2836-2843
    • Bellosillo, B.1    Villamor, N.2    Colomer, D.3    Pons, G.4    Montserrat, E.5    Gil, J.6
  • 18
    • 0035179950 scopus 로고    scopus 로고
    • DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited byfludarabine and clofarabine
    • Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited byfludarabine and clofarabine. Clin. Cancer Res. 7(11), 3580-3589 (2001).
    • (2001) Clin. Cancer Res. , vol.7 , Issue.11 , pp. 3580-3589
    • Yamauchi, T.1    Nowak, B.J.2    Keating, M.J.3    Plunkett, W.4
  • 19
    • 0035282055 scopus 로고    scopus 로고
    • Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
    • O'Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 1414-1420 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1414-1420
    • O'Brien, S.M.1    Kantarjian, H.M.2    Cortes, J.3
  • 20
    • 31544434508 scopus 로고    scopus 로고
    • Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
    • Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107, 885-891 (2006).
    • (2006) Blood , vol.107 , pp. 885-891
    • Eichhorst, B.F.1    Busch, R.2    Hopfinger, G.3
  • 21
    • 33947541773 scopus 로고    scopus 로고
    • Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
    • Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25, 793-798 (2007).
    • (2007) J. Clin. Oncol. , vol.25 , pp. 793-798
    • Flinn, I.W.1    Neuberg, D.S.2    Grever, M.R.3
  • 22
    • 34447530283 scopus 로고    scopus 로고
    • Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial
    • Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370, 230-239 (2007).
    • (2007) Lancet , vol.370 , pp. 230-239
    • Catovsky, D.1    Richards, S.2    Matutes, E.3
  • 23
    • 33745942111 scopus 로고    scopus 로고
    • Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)
    • Robak T, Blonski JZ, Gora-Tybor et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108, 473-479 (2006).
    • (2006) Blood , vol.108 , pp. 473-479
    • Robak, T.1    Gora-Tybor, B.J.2
  • 24
    • 0037214931 scopus 로고    scopus 로고
    • Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia
    • DOI 10.1002/cncr.11000
    • Montillo M, Tedeschi A, O'Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97, 114-120 (2003). (Pubitemid 36033870)
    • (2003) Cancer , vol.97 , Issue.1 , pp. 114-120
    • Montillo, M.1    Tedeschi, A.2    O'Brien, S.3    Di Raimondo, F.4    Lerner, S.5    Ferrajoli, A.6    Morra, E.7    Keating, M.J.8
  • 25
    • 0036430207 scopus 로고    scopus 로고
    • Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia
    • Robak T, B?o?ski JZ, Kasznicki M et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol. J. 3, 244-250 (2002).
    • (2002) Hematol. J. , vol.3 , pp. 244-250
    • Robak, T.1    Boski, J.Z.2    Kasznicki, M.3
  • 26
    • 58949092546 scopus 로고    scopus 로고
    • Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: Report from the Polish Adult Leukemia Group
    • Robak T, Blonski JZ, Wawrzyniak E et al. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. Cancer 115, 94-100 (2009).
    • (2009) Cancer , vol.115 , pp. 94-100
    • Robak, T.1    Blonski, J.Z.2    Wawrzyniak, E.3
  • 27
    • 77951628255 scopus 로고    scopus 로고
    • Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: A Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    • Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J. Clin. Oncol. 28, 1861-1869 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1861-1869
    • Robak, T.1    Jamroziak, K.2    Gora-Tybor, J.3
  • 28
    • 0038514130 scopus 로고    scopus 로고
    • Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia
    • Weiss MA, Maslak, P, Jurcic JG et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21, 1278-1284 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , pp. 1278-1284
    • Weiss, M.A.1    Maslak, P.2    Jurcic, J.G.3
  • 29
    • 72149089893 scopus 로고    scopus 로고
    • Current and emerging treatments for chronic lymphocytic leukaemia
    • Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 69, 2415-2449 (2009).
    • (2009) Drugs , vol.69 , pp. 2415-2449
    • Robak, T.1    Jamroziak, K.2    Robak, P.3
  • 30
    • 34249655671 scopus 로고    scopus 로고
    • Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    • Alinari L, Lapalombella R, Andritsos L et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26, 3644-3653 (2007).
    • (2007) Oncogene , vol.26 , pp. 3644-3653
    • Alinari, L.1    Lapalombella, R.2    Andritsos, L.3
  • 31
    • 48849109653 scopus 로고    scopus 로고
    • Alemtuzumab for B-cell chronic lymphocytic leukemia
    • Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 8(7), 1033-1051 (2008).
    • (2008) Expert Rev. Anticancer Ther. , vol.8 , Issue.7 , pp. 1033-1051
    • Robak, T.1
  • 34
    • 0142180086 scopus 로고    scopus 로고
    • Store-operated cation entry mediated by CD20 in membrane rafts
    • Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 278, 42427-42434 (2003).
    • (2003) J. Biol. Chem. , vol.278 , pp. 42427-42434
    • Li, H.1    Ayer, L.M.2    Lytton, J.3    Deans, J.P.4
  • 35
    • 0038446696 scopus 로고    scopus 로고
    • Circulating CD20 is detectable in the plasma of patients with chromic lymphocytic leukemia and its prognostic significance
    • Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chromic lymphocytic leukemia and its prognostic significance. Blood 101, 2507-2513 (2003).
    • (2003) Blood , vol.101 , pp. 2507-2513
    • Manshouri, T.1    Do, K.A.2    Wang, X.3
  • 36
    • 0034951864 scopus 로고    scopus 로고
    • Mechanism of action of rituximab
    • Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 12(Suppl. 2), 1-4 (2001).
    • (2001) Anticancer Drugs , vol.12 , Issue.SUPPL. 2 , pp. 1-4
    • Maloney, D.G.1
  • 37
    • 0028057250 scopus 로고
    • Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
    • Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
    • (1994) Blood , vol.83 , pp. 435-445
    • Reff, M.E.1    Carner, K.2    Chambers, K.S.3
  • 38
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis
    • Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95, 3900-3908 (2000).
    • (2000) Blood , vol.95 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3
  • 39
    • 0037306946 scopus 로고    scopus 로고
    • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    • Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101, 1045-1052 (2003).
    • (2003) Blood , vol.101 , pp. 1045-1052
    • Cragg, M.S.1    Morgan, S.M.2    Chan, H.T.3
  • 40
    • 0037306893 scopus 로고    scopus 로고
    • In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas
    • Manches O, Lui G, Chapero L et al. In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood 101, 949-954 (2003).
    • (2003) Blood , vol.101 , pp. 949-954
    • Manches, O.1    Lui, G.2    Chapero, L.3
  • 41
    • 0032030699 scopus 로고    scopus 로고
    • Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
    • Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91, 1644-1652 (1998).
    • (1998) Blood , vol.91 , pp. 1644-1652
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 42
    • 0034104375 scopus 로고    scopus 로고
    • Signaling events involved in anti-CD20 induced apoptosis of malignant human B-cells
    • Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20 induced apoptosis of malignant human B-cells. Cancer Immunol. Immunother. 48, 673-683 (2000).
    • (2000) Cancer Immunol. Immunother. , vol.48 , pp. 673-683
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 43
    • 12744279711 scopus 로고    scopus 로고
    • Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells
    • Smolewski P, Szmigielska-Kap?on A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 40, 87-100 (2005).
    • (2005) Leuk. Lymphoma , vol.40 , pp. 87-100
    • Smolewski, P.1    Szmigielska-Kapon, A.2    Cebula, B.3
  • 44
    • 0036154263 scopus 로고    scopus 로고
    • Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement and caspases
    • Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 87, 33-43 (2002).
    • (2002) Haematologica , vol.87 , pp. 33-43
    • Chow, K.U.1    Sommerlad, W.D.2    Boehrer, S.3
  • 45
    • 0033794618 scopus 로고    scopus 로고
    • Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxlyline and rituximab
    • Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxlyline and rituximab. Anticancer Res. 20, 2961-2966 (2000).
    • (2000) Anticancer Res. , vol.20 , pp. 2961-2966
    • Alas, S.1    Bonavida, B.2    Emmanouilides, C.3
  • 46
    • 0034796371 scopus 로고    scopus 로고
    • Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone
    • Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 11, 800-809 (2001).
    • (2001) Br. J. Haematol. , vol.11 , pp. 800-809
    • Di Gaetano, N.1    Xiao, Y.2    Erba, E.3
  • 47
    • 0036340530 scopus 로고    scopus 로고
    • In vitro studies with bendamustine: Enhanced activity in combination with rituximab
    • Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin. Oncol. 29(4 Suppl. 13), 12-14 (2002).
    • (2002) Semin. Oncol. , vol.29 , Issue.4 SUPPL. 13 , pp. 12-14
    • Rummel, M.J.1    Chow, K.U.2    Hoelzer, D.3    Mitrou, P.S.4    Weidmann, E.5
  • 48
    • 0034890639 scopus 로고    scopus 로고
    • Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells
    • Shan D, Gopal AK, Press OW. Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin. Cancer Res. 7, 2490-2495 (2001).
    • (2001) Clin. Cancer Res. , vol.7 , pp. 2490-2495
    • Shan, D.1    Gopal, A.K.2    Press, O.W.3
  • 49
    • 0030800131 scopus 로고    scopus 로고
    • Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    • Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12, 177-186 (1997).
    • (1997) Cancer Biother. Radiopharm. , vol.12 , pp. 177-186
    • Demidem, A.1    Lam, T.2    Alas, S.3
  • 50
    • 0034467186 scopus 로고    scopus 로고
    • Chemotherapy sensitization by rituximab: Experimental and clinical evidence
    • Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin. Oncol. 27(Suppl. 12), 30-36 (2000).
    • (2000) Semin. Oncol. , vol.27 , Issue.SUPPL. 12 , pp. 30-36
    • Wilson, W.H.1
  • 51
    • 7144250528 scopus 로고    scopus 로고
    • Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
    • The IDEC-C2B8 Study Group
    • Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann. Oncol. 9, 527-534 (1998).
    • (1998) Ann. Oncol. , vol.9 , pp. 527-534
    • Tobinai, K.1    Kobayashi, Y.2    Narabayashi, M.3
  • 53
    • 0035871445 scopus 로고    scopus 로고
    • Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
    • Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19, 2153-2164 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , pp. 2153-2164
    • Byrd, J.C.1    Murphy, T.2    Howard, R.S.3
  • 54
    • 0034043849 scopus 로고    scopus 로고
    • Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab
    • Herold M, Schulze A, Hartwig K, Anger G. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab. Ann. Hematol. 79, 332-335 (2000).
    • (2000) Ann. Hematol. , vol.79 , pp. 332-335
    • Herold, M.1    Schulze, A.2    Hartwig, K.3    Anger, G.4
  • 55
    • 0036757311 scopus 로고    scopus 로고
    • Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study
    • Itala M, Geisler CH, Kimby E et al. Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol. 69, 129-134 (2002).
    • (2002) Eur. J. Haematol. , vol.69 , pp. 129-134
    • Itala, M.1    Geisler, C.H.2    Kimby, E.3
  • 56
    • 0036839469 scopus 로고    scopus 로고
    • Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
    • Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100, 3115-3120 (2002).
    • (2002) Blood , vol.100 , pp. 3115-3120
    • Schulz, H.1    Klein, S.K.2    Rehwald, U.3
  • 57
    • 0037220152 scopus 로고    scopus 로고
    • Randomized Phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712)
    • Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 101, 6-14 (2003).
    • (2003) Blood , vol.101 , pp. 6-14
    • Byrd, J.C.1    Peterson, B.L.2    Morrison, V.A.3
  • 58
    • 29144449249 scopus 로고    scopus 로고
    • The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia
    • Del Poeta G, DelPrincipe MI, Consalvo MA et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer 104, 2743-2752 (2005).
    • (2005) Cancer , vol.104 , pp. 2743-2752
    • Del Poeta, G.1    Delprincipe, M.I.2    Consalvo, M.A.3
  • 59
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective analysis of CALGB 9712 and CALGB 9011
    • Byrd J, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 105, 49-53 (2005).
    • (2005) Blood , vol.105 , pp. 49-53
    • Byrd, J.1    Rai, K.2    Peterson, B.L.3
  • 60
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
    • (2005) J. Clin. Oncol. , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3
  • 62
    • 51649093353 scopus 로고    scopus 로고
    • Long term results of the fludarabine, cyclophosphamide and rituximab as initial therapy of chric lymphocytic leukemia
    • Tam CS, O'Brien S Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab as initial therapy of chric lymphocytic leukemia. Blood 112, 975-980 (2008).
    • (2008) Blood , vol.112 , pp. 975-980
    • Tam, C.S.1    O'Brien Wierda, S.W.2
  • 63
    • 76949091824 scopus 로고    scopus 로고
    • First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase iii trial on behalf of an international group of investigators and the german cll study group
    • Abstract 535
    • Hallek M, Fingerle-Rowson G, Fink AM et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized Phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. Blood 114 (2009) (Abstract 535).
    • (2009) Blood , vol.114
    • Hallek, M.1    Fingerle-Rowson, G.2    Fink, A.M.3
  • 64
    • 70350259810 scopus 로고    scopus 로고
    • Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - A prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial
    • Abstract 326
    • Boettcher S, Fischer K, Stilgenbauer S et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood (ASH Annual Meeting Abstracts) 112 (2008) (Abstract 326).
    • (2008) Blood (ASH Annual Meeting Abstracts) , vol.112
    • Boettcher, S.1    Fischer, K.2    Stilgenbauer, S.3
  • 65
    • 77950478885 scopus 로고    scopus 로고
    • Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia
    • Robak T, Dmoszynska A, Solal-Celigny A et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1756-1765 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1756-1765
    • Robak, T.1    Dmoszynska, A.2    Solal-Celigny, A.3
  • 66
    • 76949094333 scopus 로고    scopus 로고
    • FC-g receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone
    • Abstract 2338
    • Dornan D, Spleiss O, Yeh R-F T et al. FC-g receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 2338).
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114
    • Dornan, D.1    Spleiss, O.2    Yeh -F, R.T.3
  • 67
    • 77958050280 scopus 로고    scopus 로고
    • Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone
    • Abstract 1368
    • Robak T, Aultman R, Oertel SHK et al. Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone. Blood (ASH Annual Meeting Abstracts) 114 (2009) (Abstract 1368).
    • (2009) Blood (ASH Annual Meeting Abstracts) , vol.114
    • Robak, T.1    Aultman, R.2    Oertel, S.H.K.3
  • 68
    • 59149090791 scopus 로고    scopus 로고
    • Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia
    • Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27, 498-503 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 498-503
    • Foon, K.A.1    Boyiadzis, M.2    Land, S.R.3
  • 69
    • 59449110380 scopus 로고    scopus 로고
    • Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
    • Tsimberidou AM, Tam C, Abruzzo LV et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115, 373-380 (2009).
    • (2009) Cancer , vol.115 , pp. 373-380
    • Tsimberidou, A.M.1    Tam, C.2    Abruzzo, L.V.3
  • 70
    • 77649184591 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years
    • Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk. Res. 34, 284-228 (2010).
    • (2010) Leuk. Res. , vol.34 , pp. 284-228
    • Faderl, S.1    Wierda, W.2    O'Brien, S.3    Ferrajoli, A.4    Lerner, S.5    Keating, M.J.6
  • 71
    • 74549145611 scopus 로고    scopus 로고
    • Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia
    • Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27, 4578-4584 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4578-4584
    • Bosch, F.1    Abrisqueta, P.2    Villamor, N.3
  • 72
    • 77950546050 scopus 로고    scopus 로고
    • NCRI CLL201 Trial: A randomized Phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
    • Abstract 752
    • Hillmen P, Pcock C, Cohen D et al. NCRI CLL201 Trial: a randomized Phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood 110, 231a (2007) (Abstract 752).
    • (2007) Blood , vol.110 , Issue.231
    • Hillmen, P.1    Pcock, C.2    Cohen, D.3
  • 73
    • 40449108219 scopus 로고    scopus 로고
    • Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
    • DOI 10.2174/156800908783769319
    • Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr. Cancer Drug Targets. 8, 156-171 (2008). (Pubitemid 351347252)
    • (2008) Current Cancer Drug Targets , vol.8 , Issue.2 , pp. 156-171
    • Robak, T.1
  • 74
    • 38049094162 scopus 로고    scopus 로고
    • Combined cyclophosphamide fludarabine alemtuzumab and rituximab (CFAR) an active regimen for heavily treated patients with CLL
    • Abstract 31
    • Wierda WG, O'Brien SM, Faderl SH et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108, 14a (2006) (Abstract 31).
    • (2006) Blood , vol.108 , Issue.14 A
    • Wierda, W.G.1    O'Brien, S.M.2    Faderl, S.H.3
  • 75
    • 38949180269 scopus 로고    scopus 로고
    • Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines
    • Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111, 1594-1602 (2008).
    • (2008) Blood , vol.111 , pp. 1594-1602
    • Pathan, N.I.1    Chu, P.2    Hariharan, K.3    Cheney, C.4    Molina, A.5    Byrd, J.6
  • 76
    • 77449133613 scopus 로고    scopus 로고
    • Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia
    • Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115, 489-495 (2010).
    • (2010) Blood , vol.115 , pp. 489-495
    • Byrd, J.C.1    Kipps, T.J.2    Flinn, I.W.3
  • 77
    • 33846258434 scopus 로고    scopus 로고
    • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    • Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
    • (2007) Blood , vol.109 , pp. 405-411
    • Kay, N.E.1    Geyer, S.M.2    Call, T.G.3
  • 78
    • 34249042684 scopus 로고    scopus 로고
    • Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
    • Shanafelt TD, Lin T, Geyer SM et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109, 2291-2298 (2007).
    • (2007) Cancer , vol.109 , pp. 2291-2298
    • Shanafelt, T.D.1    Lin, T.2    Geyer, S.M.3
  • 79
    • 33645732715 scopus 로고    scopus 로고
    • Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    • Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 24, 1575-1581 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1575-1581
    • Lamanna, N.1    Kalaycio, M.2    Maslak, P.3
  • 80
    • 33749600951 scopus 로고    scopus 로고
    • Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
    • Robak T, Smolewski P, Cebula B et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 107, 1542-1550 (2006).
    • (2006) Cancer , vol.107 , pp. 1542-1550
    • Robak, T.1    Smolewski, P.2    Cebula, B.3
  • 81
    • 34447326480 scopus 로고    scopus 로고
    • Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    • Robak T, Smolewski P, Cebula B et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol. 79, 107-113 (2007).
    • (2007) Eur. J. Haematol. , vol.79 , pp. 107-113
    • Robak, T.1    Smolewski, P.2    Cebula, B.3
  • 82
    • 70350132633 scopus 로고    scopus 로고
    • Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
    • Castro JE, James DF, Sandoval-Sus JD et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 23, 1779-1789 (2009).
    • (2009) Leukemia , vol.23 , pp. 1779-1789
    • Castro, J.E.1    James, D.F.2    Sandoval-Sus, J.D.3
  • 83
    • 56249095457 scopus 로고    scopus 로고
    • Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
    • Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22, 2048-2053 (2008).
    • (2008) Leukemia , vol.22 , pp. 2048-2053
    • Castro, J.E.1    Sandoval-Sus, J.D.2    Bole, J.3    Rassenti, L.4    Kipps, T.J.5
  • 84
    • 37149029392 scopus 로고    scopus 로고
    • Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
    • Bowen DA, Call TG, Jenkins GD et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk. Lymphoma 48, 2412-2417 (2007).
    • (2007) Leuk. Lymphoma , vol.48 , pp. 2412-2417
    • Bowen, D.A.1    Call, T.G.2    Jenkins, G.D.3
  • 85
    • 0036154263 scopus 로고    scopus 로고
    • Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases
    • Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87, 33-43 (2002).
    • (2002) Haematologica , vol.87 , pp. 33-43
    • Chow, K.U.1    Sommerlad, W.D.2    Boehrer, S.3
  • 86
    • 64349123114 scopus 로고    scopus 로고
    • Bendamustine in the treatment of chronic lymphocytic leukemia
    • Knauf W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 9(2), 165-174 (2009).
    • (2009) Expert Rev. Anticancer Ther. , vol.9 , Issue.2 , pp. 165-174
    • Knauf, W.1
  • 87
    • 65749110753 scopus 로고    scopus 로고
    • Bendamustine in combination with rituximab (BR)for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre Phase II trial of the German CLL Study Group (GCLLSG)
    • Abstract
    • Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood 112, 330 (2008) (Abstract).
    • (2008) Blood , vol.112 , pp. 330
    • Fischer, K.1    Stilgenbauer, S.2    Schweighofer, C.D.3
  • 88
    • 77950321929 scopus 로고    scopus 로고
    • Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter Phase II trial of the German CLL Study Group (GCLLSG)
    • Abstract 205
    • Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL Study Group (GCLLSG). Blood 114, 89 (2009) (Abstract 205).
    • (2009) Blood , vol.114 , pp. 89
    • Fischer, K.1    Cramer, P.2    Stilgenbauer, S.3
  • 89
    • 0038724252 scopus 로고    scopus 로고
    • Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    • Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101, 3413-3415 (2003).
    • (2003) Blood , vol.101 , pp. 3413-3415
    • Faderl, S.1    Thomas, D.A.2    O'Brien, S.3
  • 90
    • 8644274039 scopus 로고    scopus 로고
    • A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    • Nabhan C, Patton D, Gordon LI et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk. Lymphoma 45, 2269-2273 (2004).
    • (2004) Leuk. Lymphoma , vol.45 , pp. 2269-2273
    • Nabhan, C.1    Patton, D.2    Gordon, L.I.3
  • 91
    • 77952573871 scopus 로고    scopus 로고
    • Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence
    • Faderl S, Ferrajoli A, Wierda W et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10), 2360-2365 (2010).
    • (2010) Cancer , vol.116 , pp. 2360-2365
    • Faderl, S.1    Ferrajoli, A.2    Wierda, W.3
  • 92
    • 77954659957 scopus 로고    scopus 로고
    • Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy
    • Ysebaert L, Gross E, Kühlein E et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 24, 1310-1316 (2010).
    • (2010) Leukemia , vol.24 , pp. 1310-1316
    • Ysebaert, L.1    Gross, E.2    Kühlein, E.3
  • 93
    • 33645982603 scopus 로고    scopus 로고
    • Infectious complications of chronic lymphocytic leukemia
    • Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin. Oncol. 33, 240-249 (2006).
    • (2006) Semin. Oncol. , vol.33 , pp. 240-249
    • Wadhwa, P.D.1    Morrison, V.A.2
  • 94
    • 77956413908 scopus 로고    scopus 로고
    • Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 Phase III randomized intergroup study
    • van Oers MH, Van Glabbeke M, Giurgea L et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J. Clin. Oncol. 28, 2853-2858 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 2853-2858
    • Van Oers, M.H.1    Van Glabbeke, M.2    Giurgea, L.3
  • 95
    • 67949094458 scopus 로고    scopus 로고
    • Novel drugs for chronic lymphoid leukemias: Mechanism of action and therapeutic activity
    • Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr. Med. Chem. 16, 2212-2234 (2009).
    • (2009) Curr. Med. Chem. , vol.16 , pp. 2212-2234
    • Robak, T.1
  • 96
    • 38949185742 scopus 로고    scopus 로고
    • Safety and efficacy ofofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia A Phase I-II study
    • Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy ofofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A Phase I-II study. Blood 11, 1094-1100 (2008).
    • (2008) Blood , vol.11 , pp. 1094-1100
    • Coiffier, B.1    Lepretre, S.2    Pedersen, L.M.3
  • 97
    • 77950502126 scopus 로고    scopus 로고
    • Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
    • Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1749-1755 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1749-1755
    • Wierda, W.G.1    Kipps, T.J.2    Mayer, J.3
  • 98
    • 70449603373 scopus 로고    scopus 로고
    • GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo
    • Abstract 2348
    • Umana P, Moessner E, Bruenker P et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood 110, 694a (2007) (Abstract 2348).
    • (2007) Blood , vol.110
    • Umana, P.1    Moessner, E.2    Bruenker, P.3
  • 99
    • 67649575638 scopus 로고    scopus 로고
    • A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease
    • Abstract 234
    • Salles GA, Morschhauser F, Cartron G et al. A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 112, 93 (2008) (Abstract 234).
    • (2008) Blood , vol.112 , pp. 93
    • Salles, G.A.1    Morschhauser, F.2    Cartron, G.3
  • 100
    • 67650657179 scopus 로고    scopus 로고
    • GA-101, a third-generation, humanized and glyco-engineered anti CD20 mAb for the treatment of B-cell lymphoid malignancies
    • Website
    • Robak T. GA-101, a third-generation, humanized and glyco-engineered anti CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin. Investig. Drugs 10, 588-596 (2009). Website
    • (2009) Curr. Opin. Investig. Drugs , vol.10 , pp. 588-596
    • Robak, T.1
  • 101
    • 77958068175 scopus 로고    scopus 로고
    • Biogen Idec This study has been terminated. Received: 19 October last updated: 12 August 2010 Lumiliximab with Fludarabine Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)
    • Biogen Idec. ClinicalTrials.gov identifier: NCT00391066. Lumiliximab with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID). This study has been terminated. Received: 19 October 2006; last updated: 12 August 2010 http://clinicaltrials.gov
    • (2006) ClinicalTrials.gov Identifier: NCT00391066


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.